Bakers Union and FELRA Health and Welfare fund

Quarterly Review
January - September 2020

December 9, 2020

OPTUMRx®

Agenda: 3Q2020 Quarterly Review

Agenda
1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Mandatory Mail options
6. Clinical Opportunities a. Opioid Management Program b. Formulary – Select to Premium c. ESP (enhanced savings program) d. Optum Perks

Your OptumRx Team

- **Holly Agoney**
  Strategic Account Executive
- **Fabian Gonzalez**
  Pharmacy Service Specialist
- **Adam Towner**
  Director, Client Management

OPTUMRx®

Current Plan Design

- Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	$2,000 per year for Growth Hormones medications only
Max out of Pocket:	$2,850 Individual / $5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	$2,000 per year for Growth Hormones medications only
Max out of Pocket:	$1,850 Individual / $3,700 Family

Co-pays

Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
Retail		Mail	
*Generic:	$10	*Generic:	$20
*Brand:	$15	*Brand:	$30
*NP Brand:	$30	*NP Brand:	$60
*Specialty:	Run trial claim for co-pay	*Specialty:	N/A

Plan 3 (group BFWRX3):	
Retail / Mail	
*Generic:	5% ($5 min.)
*Brand:	15% ($15 min.)
*NP Brand:	25% ($25 min.)
*Specialty:	Run trial claim for co-pay

- Select Formulary
- **Effective 7/1/19**
  - Diabetes Program
  - Comprehensive Ums
  - Vigilant Program
  - RxOTC Program
- **Effective 8/1/2020**
  - Orphan Drug Program

OPTUMRx®

Key Discussion Topics

- Per Member Per Month (PMPM) trend = 14.3% Specialty trend = 19.9%
- Specialty accounted for 0.9% of claims
- Top 5 disease states accounted for 70% of total plan paid
  - Top traditional disease state: Diabetes
  - Top specialty disease state: Inflammatory Conditions
- UM Outcome Savings = $64,900
  - This is for all PA, ST, QL currently in place

Key Statistics - Performance Summary

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare fund has experienced period over period.

- Eligibility has decreased by -76.
- Number of utilizers has decreased by -22.

Total Rxs

CURRENT
6,567

PREVIOUS
6,646

PERCENT CHANGE
-1.2%

Total plan paid

CURRENT
$811,658

PREVIOUS
$787,636

PERCENT CHANGE
3.1%

Utilizers

CURRENT
436

PREVIOUS
458

PERCENT CHANGE
-4.8%

OPTUMRx®

Key Statistics with Benchmark Comparison

Your benchmark comparison

LABOR AND TRUST

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 14.3%, compared to the benchmark trend of 7.2%
- Member Paid Share changed by -5.1% period over period, compared to the benchmark of -5.7%

				Benchmark	
Key statistics	**Current**	**Previous**	**Percent change**	**Current**	**Percent change**
Average age	41.6	41.0	1.6%	37.9	-1.0%
Plan paid PMPM	$129.84	$113.61	14.3%	$87.92	7.2%
Plan paid per Rx	$123.60	$118.51	4.3%	$125.08	9.5%
Rxs PMPM	1.05	0.96	9.6%	0.70	-2.0%
Average days supply	26.6	26.8	-0.5%	40.0	5.5%
Days supply PMPM	28.0	25.7	9.1%	28.1	3.3%
Member paid share	7.4%	7.8%	-5.1%	8.8%	-5.7%
Member paid per Rx	$9.84	$10.07	-2.3%	$12.08	2.6%
Generic dispensing rate	84.5%	84.5%	0.0%	86.4%	0.7%
Home delivery rate	1.0%	1.1%	-9.1%	9.1%	2.8%
Retail 90 rate	0.3%	0.2%	50.0%	14.9%	17.5%
Percent of specialty plan paid	40.9%	39.0%	4.9%	34.4%	10.2%

OPTUMRx®

Key Specialty Statistics

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare fund has experienced period over period.

- Eligibility has decreased by -76.
- Number of utilizers has increased by 2.

Total Rxs

CURRENT
59

PREVIOUS
50

PERCENT CHANGE
18.0%

Total plan paid

CURRENT
$331,737

PREVIOUS
$306,832

PERCENT CHANGE
8.1%

Utilizers

CURRENT
12

PREVIOUS
10

PERCENT CHANGE
20.0%

OPTUMRx®

Key Specialty Statistics with Benchmark Comparison

Your benchmark comparison

LABOR AND TRUST

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 19.9%, compared to the benchmark trend of 18.2%
- Member Paid Share changed by -57.1% period over period, compared to the benchmark of -2.0%

				Benchmark	
Key statistics	**Current**	**Previous**	**Percent change**	**Current**	**Percent change**
Average age	41.6	41.0	1.6%	37.9	-1.0%
Plan paid PMPM	$53.07	$44.26	19.9%	$30.27	18.2%
Plan paid per Rx	$5,622.66	$6,136.65	-8.4%	$5,199.24	8.5%
Rxs PMPM	0.009	0.007	28.6%	0.006	8.9%
Average days supply	29.0	28.1	3.3%	32.1	3.5%
Days supply PMPM	0.3	0.2	35.0%	0.2	12.7%
Member paid share	0.3%	0.7%	-57.1%	3.7%	-2.0%
Member paid per Rx	$14.41	$42.72	-66.3%	$197.04	6.3%
Generic dispensing rate	11.9%	4.0%	197.5%	31.2%	-6.6%
Home delivery rate	0.0%	0.0%	0.0%	1.3%	-7.5%
Retail 90 rate	1.7%	0.0%	0.0%	5.1%	22.7%

Trend Summary

Your benchmark comparison

LABOR AND TRUST

Trend

Plan paid PMPM has increased 14.3% over the previous period driven primarily by cost in traditional and utilization for specialty.

Specialty represents 0.9% of claims.

+7.1% over benchmark **+8.4%** over benchmark **+1.7%** over benchmark

OPTUMRx®

Total Trend Components

Your benchmark comparison

LABOR AND TRUST

Total trend: 14.3%

- Bakers Union and FELRA Health and Welfare fund's overall trend of 14.3% was 7.1% higher than benchmark
- Specialty spend influenced the trend contributing 54.3% (-24.3% lower than benchmark)
- Traditional trend contributed 45.7% (24.3% higher than benchmark)



OPTUMRx®

Traditional vs. Specialty Trend Components

Your benchmark comparison
LABOR AND TRUST

Traditional trend: 10.7%

- Traditional trend contributed 45.7% to the overall trend (14.3%)
- Traditional accounts for 59.1% of overall total plan paid and was down from 61.0% in the prior period



Specialty trend: 19.9%

- Specialty trend contributed 54.3% to the overall trend (14.3%)
- Specialty accounts for 40.9% of overall total plan paid and was up from 39.0% in the prior period



OPTUMRx®

Top Disease States

Top 5 disease states account for 70% of total Plan Paid

- Inflammatory Conditions accounts for 34.0% of total plan paid, with trend driven by Utilization. HUMIRA PEN was the top drug
- Diabetes accounts for 18.9% of total plan paid, with trend driven by Utilization. HUMALOG MIX 50/50 KWIKPEN was the top drug

Traditional

Specialty

Sort by: Plan Paid Contribution to trend



OPTUMRx®

Top 20 Drugs

Rank												Trend components		
Cu	Pv	Drug name	Therapy class	Utlzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr PMPM	Prev PMPM	BOB PMPM	% Trend	Top driver	% Top driver
1	4	HUMIRA PEN	Chronic Inflammatory Disease	2	17	28.0	$97,803	$5,753	$15.65	$6.20	$3.75	152.5%	Utlzn	135.7%
2	3	TREMFYA	Chronic Inflammatory Disease	1	5	30.0	$58,495	$11,699	$9.36	$6.49	$0.41	44.1%	Utlzn	38.6%
3	2	OTEZLA	Chronic Inflammatory Disease	2	14	30.0	$51,697	$3,693	$8.27	$6.59	$0.70	25.6%	Utlzn	19.4%
4	N/A	SUPPRELIN LA	LHRH/GNRH Agonist/Antagonists	1	1	90.0	$40,631	$40,631	$6.50	$0.00	$0.01	N/A	Cost	0.0%
5	5	SIMPONI ARIA	Chronic Inflammatory Disease	1	5	30.0	$38,658	$7,732	$6.18	$5.37	$0.02	15.3%	Utlzn	10.9%
6	7	STRIBILD	HIV-Multiclass Combo	1	10	30.0	$33,262	$3,326	$5.32	$3.51	$0.08	51.5%	Utlzn	38.6%
7	25	DUPIXENT	Chronic Inflammatory Disease	1	9	28.0	$29,423	$3,269	$4.71	$0.92	$0.69	414.1%	Utlzn	565.5%
8	9	HUMALOG MIX 50/ 50 KWIKPEN	Insulin	2	14	39.0	$18,721	$1,337	$2.99	$2.14	$0.01	39.9%	Utlzn	43.7%
9	11	VICTOZA	GLP-1 Receptor Agonists	2	17	30.0	$16,017	$942	$2.56	$2.07	$0.83	23.8%	Utlzn	17.8%
10	21	HUMULIN R U-500 (CONCENTRATED)	Insulin	1	10	30.0	$14,549	$1,455	$2.33	$1.05	$0.04	121.8%	Utlzn	121.8%
11	19	JARDIANCE	SGLT-2 Inhibitors & Combos	5	27	30.0	$13,560	$502	$2.17	$1.23	$1.42	76.6%	Utlzn	66.4%
12	1	IBRANCE	Oncology	1	1	28.0	$13,132	$13,132	$2.10	$14.34	$0.66	-85.4%	Utlzn	-86.1%
13	17	JANUVIA	DPP-4 Inhibitors & Combos	5	29	29.0	$12,771	$440	$2.04	$1.31	$1.42	56.2%	Utlzn	48.8%
14	16	REXULTI	Atypical Antipsychotics	1	11	30.0	$11,400	$1,036	$1.82	$1.31	$0.16	39.0%	Utlzn	35.6%
15	13	SYMBICORT	Inhaled Asthma/COPD Combo	6	30	30.0	$9,967	$332	$1.59	$1.52	$0.78	5.1%	Utlzn	4.4%
16	62	LANTUS	Insulin	1	12	28.0	$9,357	$780	$1.50	$0.31	$0.24	383.9%	Cost	339.9%
17	12	ABSORICA	Acne Products	1	4	30.0	$7,853	$1,963	$1.26	$1.77	$0.05	-29.1%	Utlzn	-26.1%
18	37	BREO ELLIPTA	Inhaled Asthma/COPD Combo	5	16	41.0	$7,382	$461	$1.18	$0.59	$0.53	98.6%	Utlzn	87.7%
19	41	JANUMET XR	DPP-4 Inhibitors & Combos	2	16	30.0	$7,261	$454	$1.16	$0.56	$0.22	107.2%	Utlzn	97.2%
20	18	INVOKANA	SGLT-2 Inhibitors & Combos	2	14	30.0	$6,930	$495	$1.11	$1.23	$0.50	-10.0%	Utlzn	-13.7%

Top 20 Traditional Drugs

Rank												Trend components		
Cu	Pv	Drug name	Therapy class	Utlzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr PMPM	Prev PMPM	BOB PMPM	% Trend	Top driver	% Top driver
1	2	STRIBILD	HIV-Multiclass Combo	1	10	30.0	$33,262	$3,326	$5.32	$3.51	$0.08	51.5%	Utlzn	38.6%
2	3	HUMALOG MIX 50/ 50 KWIKPEN	Insulin	2	14	39.0	$18,721	$1,337	$2.99	$2.14	$0.01	39.9%	Utlzn	43.7%
3	5	VICTOZA	GLP-1 Receptor Agonists	2	17	30.0	$16,017	$942	$2.56	$2.07	$0.83	23.8%	Utlzn	17.8%
4	14	HUMULIN R U-500 (CONCENTRATED)	Insulin	1	10	30.0	$14,549	$1,455	$2.33	$1.05	$0.04	121.8%	Utlzn	121.8%
5	12	JARDIANCE	SGLT-2 Inhibitors & Combos	5	27	30.0	$13,560	$502	$2.17	$1.23	$1.42	76.6%	Utlzn	66.4%
6	10	JANUVIA	DPP-4 Inhibitors & Combos	5	29	29.0	$12,771	$440	$2.04	$1.31	$1.42	56.2%	Utlzn	48.8%
7	9	REXULTI	Atypical Antipsychotics	1	11	30.0	$11,400	$1,036	$1.82	$1.31	$0.16	39.0%	Utlzn	35.6%
8	7	SYMBICORT	Inhaled Asthma/COPD Combo	6	30	30.0	$9,967	$332	$1.59	$1.52	$0.78	5.1%	Utlzn	4.4%
9	53	LANTUS	Insulin	1	12	28.0	$9,357	$780	$1.50	$0.31	$0.24	383.9%	Cost	339.9%
10	6	ABSORICA	Acne Products	1	4	30.0	$7,853	$1,963	$1.26	$1.77	$0.05	-29.1%	Utlzn	-26.1%
11	29	BREO ELLIPTA	Inhaled Asthma/COPD Combo	5	16	41.0	$7,382	$461	$1.18	$0.59	$0.53	98.6%	Utlzn	87.7%
12	33	JANUMET XR	DPP-4 Inhibitors & Combos	2	16	30.0	$7,261	$454	$1.16	$0.56	$0.22	107.2%	Utlzn	97.2%
13	11	INVOKANA	SGLT-2 Inhibitors & Combos	2	14	30.0	$6,930	$495	$1.11	$1.23	$0.50	-10.0%	Utlzn	-13.7%
14	31	BYDUREON BCISE	GLP-1 Receptor Agonists	1	9	28.0	$6,326	$703	$1.01	$0.59	$0.19	72.6%	Utlzn	66.4%
15	25	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	12	30.0	$6,256	$521	$1.00	$0.63	$0.38	57.6%	Utlzn	47.9%
16	15	DEXILANT	Proton Pump Inhibitors	3	23	30.0	$6,230	$271	$1.00	$1.03	$0.29	-3.5%	Utlzn	-8.9%
17	N/A	TRUVADA	HIV-Multiclass Combo	1	4	30.0	$6,191	$1,548	$0.99	$0.00	$0.48	N/A	Cost	0.0%
18	36	NOVOLOG FLEXPEN	Insulin	3	13	28.0	$5,451	$419	$0.87	$0.51	$0.38	71.8%	Cost	86.4%
19	8	JANUMET	DPP-4 Inhibitors & Combos	2	12	30.0	$5,446	$454	$0.87	$1.43	$0.66	-39.2%	Utlzn	-42.1%
20	18	HUMALOG KWIKPEN	Insulin	3	11	28.0	$5,192	$472	$0.83	$0.90	$0.69	-7.7%	Utlzn	-14.6%

Top 20 Specialty Drugs

Rank												Trend components		
Cu	Pv	Drug name	Therapy class	Utlzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr PMPM	Prev PMPM	BOB PMPM	% Trend	Top driver	% Top driver
1	4	HUMIRA PEN	Chronic Inflammatory Disease	2	17	28.0	$97,803	$5,753	$15.65	$6.20	$3.75	152.5%	Utlzn	135.7%
2	3	TREMFYA	Chronic Inflammatory Disease	1	5	30.0	$58,495	$11,699	$9.36	$6.49	$0.41	44.1%	Utlzn	38.6%
3	2	OTEZLA	Chronic Inflammatory Disease	2	14	30.0	$51,697	$3,693	$8.27	$6.59	$0.70	25.6%	Utlzn	19.4%
4	N/A	SUPPRELIN LA	LHRH/GNRH Agonist/Antagonists	1	1	90.0	$40,631	$40,631	$6.50	$0.00	$0.01	N/A	Cost	0.0%
5	5	SIMPONI ARIA	Chronic Inflammatory Disease	1	5	30.0	$38,658	$7,732	$6.18	$5.37	$0.02	15.3%	Utlzn	10.9%
6	8	DUPIXENT	Chronic Inflammatory Disease	1	9	28.0	$29,423	$3,269	$4.71	$0.92	$0.69	414.1%	Utlzn	565.5%
7	1	IBRANCE	Oncology	1	1	28.0	$13,132	$13,132	$2.10	$14.34	$0.66	-85.4%	Utlzn	-86.1%
8	N/A	MYCOPHENOLATE MOFETIL	Transplant	1	4	30.0	$1,725	$431	$0.28	$0.00	$0.13	N/A	Cost	0.0%
9	11	ENOXAPARIN SODIUM	Injectable Anticoagulants	2	3	9.0	$172	$57	$0.03	$0.00	$0.03	1,761.4%	Cost	1,567.7%

Mandatory Mail Options

Mandatory Mail Analysis –

- Below are the savings for the 3 different programs that are offered for MM – this is with 2 grace fills at retail and keeping the current copays in place. This was based on 224 utilizing retail maintenance members for the timeframe of Jan – Aug 2020.
  - Mail Service Saver Plus - $38,700
  - Mail Service Saver - $36,800
  - Mail Service Member Select - $21,200

- The next slide provides further information regarding these 3 mail programs

- These are great programs that provide additional savings to both the fund and the member along with the convenience of having it shipped to the members' home

Detail on the 3 Mail programs and methodology:

Savings based on book of business and not actual client experience. Plan Savings vary based on the copay design and are rounded to the nearest .5%.

1 Annual Plan Savings: Assumes Saver Penalty of two times the regular retail copay. Assumes a grace period of 2 fills. Plan Savings are approximated based on book of business, and will vary depending on actual contracted discounts and dispense fees. Plan savings are rounded to the nearest .5%

2 Plan and member paid will not include impact from other programs such as disease management or other incentive programs; therefore plan and member paid amounts may not match adjudicated claims.

3 Savings are annualized and reflect year 2 and subsequent year plan savings.

4 Due to the client size, the plan paid savings is provided only. Plan savings % is based on book of business and client copay design.

For both the Home Delivery and WAG90 modeling the model looks at the claim data where there are maintenance drug claims and provides a projection of claim movement for the maintenance claims from Retail 30 to Mail for Home Delivery and Retail 30 to Retail 90 or Mail for WAG90.

The estimated savings/impact for the member is based on that potential movement and potential penalties. It projects the copay based on the movement to Retail 90 or Mail. In addition to that with the Saver Plus program the member has the option to cover the entire cost of the drug after the grace period if they decide to remain at a Retail 30 pharmacy. For the Saver program the member has the option to continue to fill at the Retail 30 pharmacy after the grace period with increased copays. The model has actuarial calculations that determines the potential for the movement and the potential for members to remain at Retail 30 this is where you may see the estimated impact to member cost.

Program	Ease	Description
Mail Service Saver Plus	Most Restrictive	After the grace period, member covers cost of drug if filled at retail.
Mail Service Saver	Middle of the road	After the grace period, member has increased copays if filled at retail
Mail Service Member Select (MSMS)	Least Restrictive	Same as Saver Plus, except members can Opt out of the program

OPTUMRx®

Opioid Risk Management Program

Opioid Risk Management Program

2.3% of all Rx claims are filled for an Opioid

Opioid dependence can start in just a few days, and the risk of chronic opioid use increases with each additional day of opioid supplied, starting with the third day. Our Opioid Risk Management program, which includes point of sale, utilization management and retrospective drug utilization edits, are tightly aligned with CDC opioid prescribing guidelines which can help reduce exposure to excessive doses and prevent more members from transitioning from acute to chronic use.

- Opioid prescriptions account for 2.3% of all prescriptions this period, which is 1.1% lower than the benchmark
- 7 high opioid utilizers were identified this period, which is -11.6% lower than the benchmark

Opioid claims



PERCENT NON-COMPLIANT

18.2%

View details

Opioid utilizers



HIGH UTILIZERS

18.9%

7 high utilizers

-11.6% under benchmark

High utilizers – view definition

Claim breakdown



short acting opioids

74.2% of all opioid Rxs were filled for short acting opioids. **8** Rxs were for medication assisted therapy (MAT) and **1** were for rescue therapy. CDC guidelines advise prescribers to manage pain with the lowest effective dose and to avoid or carefully justify doses for chronic users >90mg MME/day.

MAT – view definition
Overdose rescue therapy – view definition
MME – view definition

Utilizers by cumulative MED

0 utilizers exceed 180 MED/day

MED Scores	<90	90-179	180-240	>240
Utilizers	36	1	0	0

MED – view definition

OPTUMRx®

Opioid Risk Management options

Highlighted indicates elements already in place

STANDARD BASE

Prevention/Education

Prescriber: several prescriber education resources via OptumRx provider portal

- Chronic pain management guidelines for prescribers

Member: education on safe opioid use and parental guidance via OptumRx member portal

- New to Therapy safe use opioids flyer
- Chronic use / pain management flyer

Pharmacies: new CDC prescribing guidelines and formulary change education

General: Optum.com opioids page including e-Book

Enhanced Point of Sale Safety Edits

Required for all Commercial + Managed Medicaid clients

- DEA Prescriber Edit: rejects controlled Rx's issued by MDs without proper controlled-Rx DEA prescribing authority
- POS CDUR Edits: Opioid + prenatal vitamin Rx
- POS CDUR Edits: Opioid secondary to a Medication Assisted Treatment (MAT) Rx
- POS CDUR Edits: Cumulative acetaminophen dose check (w/ opioid-containing drugs)
- CDUR Edit: Opioid + concurrent benzodiazepine
- Cumulative 90 MME Dose Limit across all opioid Rx's (soft reject required; PA – optional at 180 MME)

ADD-ON

Refill Window

Tighter refill window:

- 90% med exhaustion @ retail
- 80% med exhaustion @ mail – all controlled drugs

Free of Charge

Utilization Management*

CDC and FDA Guideline Alignment:

- 1st-fill: maximum 50 MME/day and 7 days supply limits on all short-acting opioids (SAO)
- Drug-specific max of 90 MME/day for chronic users

Utilization Management Edits

- PA on all long-acting opioids
- QLs on all long-acting opioids
- QLs on all opioid-based cold and cough agents + PA for kids

Free of Charge

Member Education*

Auto-generated patient letter following fill of an opioid:

- Education on appropriate use; risks; safer alternatives; proper disposal and storage
- Chronic Use / Pain Management Trigger Letter

*Buy up

Retrospective DUR*

Provider outreach regarding patient-specific opioid clinical opportunities:

- Dosing, dangerous drug combinations, therapeutic duplication, excessive early refills, prescriber/pharmacy shopping

*Buy up

Intensive Case Management*

Highest-risk utilizer intervention:

- Pharmacist case review for high-risk opioid overuse
- Prescriber outreach, consultation and action planning
- Drug-level lock-in

*Buy up

OPTUMRx®

* The "buy-ups" are annual charges

*Additional PA fees or fees may apply

Formulary
Select to Premium

Formulary - Select to Premium

Opportunities date range: Jan - Sep 2020

- OptumRx formulary options promote medication quality and safety through a clinically driven offering
- Some of our formulary options offer strategic exclusions to support member choice, minimize disruption and deliver significant client savings and value

Learn more about formulary management

Select to Premium

No change

UTILIZERS
427

RXS
6,282

% OF TOTAL RXS
96.1%

Excluded

UTILIZERS
63

RXS
253

% OF TOTAL RXS
3.9%

The OptumRx® Premium formulary offers an enhanced savings strategy that leverages exclusion capabilities with manufacturers to reduce costs, maintaining robust medication choice and promoting lower-cost alternatives. The Premium formulary is a three-tiered, partially closed formulary that includes a copay differential of at least $10 between tiers.

OPTUMRx®

Formulary - Select to Premium

Opportunities date range: Jan - Sep 2020

Therapy class	Drug name	Alternative	Disruption type	Utilizers	Rxs
Inhaled Bronchodilator	PROAIR HFA	GENERIC ALBUTEROL HFA	Excluded	12	21
Diabetes Monitoring and Testing Supplies	ONETOUCH VERIO TEST STRIPS	ASCENCIA (CONTOUR, CONTOUR NEXT) TEST STRIPS	Excluded	9	26
Inhaled Bronchodilator	VENTOLIN HFA	GENERIC ALBUTEROL HFA	Excluded	8	13
Inhaled Bronchodilator	ALBUTEROL SULFATE HFA	GENERIC ALBUTEROL HFA	Excluded	7	16
Inhaled Asthma/COPD Combo	BUDESONIDE/FORMOTEROL FUMARATE DIHYDRATE	FLUTICASONE/SALMETEROL, ADVAIR, BREO ELLIPTA, SYMBICORT	Excluded	5	10
Diabetes Monitoring and Testing Supplies	ONETOUCH ULTRA	ASCENCIA (CONTOUR, CONTOUR NEXT) TEST STRIPS	Excluded	4	14
Insulin	NOVOLOG FLEXPEN	HUMALOG	Excluded	3	13
Thyroid Hormones	SYNTHROID	LEVOTHYROXINE, LEVOXYL, UNITHROID	Excluded	3	19
Diabetes Monitoring and Testing Supplies	ONETOUCH ULTRA 2	ASCENCIA (CONTOUR, CONTOUR NEXT) BLOOD GLUCOSE MONITOR	Excluded	2	2
Contraceptives	LO LOESTRIN FE	TARINA FE, JUNEL FE, MICROGESTIN FE, AND LARIN FE	Excluded	2	8
Insulin	BASAGLAR KWIKPEN	LANTUS, TOUJEO	Excluded	2	8
Insulin	TRESIBA FLEXTOUCH	LANTUS, TOUJEO	Excluded	2	10
SGLT-2 Inhibitors & Combos	INVOKANA	FARXIGA, JARDIANCE	Excluded	2	14
Diabetes Monitoring and Testing Supplies	ACCU-CHEK GUIDE	ASCENCIA (CONTOUR, CONTOUR NEXT) BLOOD GLUCOSE MONITOR	Excluded	1	1
Diabetes Monitoring and Testing Supplies	ONETOUCH VERIO	ASCENCIA (CONTOUR, CONTOUR NEXT) BLOOD GLUCOSE MONITOR	Excluded	1	1
Diabetes Monitoring and Testing Supplies	ONETOUCH VERIO FLEX BLOOD GLUCOSE MONITORING SYSTEM	ASCENCIA (CONTOUR, CONTOUR NEXT) BLOOD GLUCOSE MONITOR	Excluded	1	1
Diabetes Monitoring and Testing Supplies	ACCU-CHEK GUIDE	ASCENCIA (CONTOUR, CONTOUR NEXT) TEST STRIPS	Excluded	1	1

OPTUMRx®

Formulary - Select to Premium

Opportunities date range: Jan - Sep 2020

Therapy class	Drug name	Alternative	Disruption type	Utilizers	Rxs
Insulin	NOVOLOG MIX 70/30	HUMALOG MIX	Excluded	1	1
Anti-Inflammatory Agents - Topical	FLECTOR	DICLOFENAC PATCH	Excluded	1	2
HIV-Multiclass Combo	DESCOVY	Please talk to your doctor about other option(s).	Excluded	1	2
Inhaled Bronchodilator	PROAIR RESPICLICK	GENERIC ALBUTEROL HFA	Excluded	1	3
Insulin	INSULIN ASPART FLEXPEN	HUMALOG	Excluded	1	3
Insulin	INSULIN LISPRO KWIKPEN	HUMALOG	Excluded	1	3
Ophthalmics - Misc.	PAZEO	AZELASTINE OPHTHALMIC SOLUTION, OLOPATADINE OPHTHALMIC SOLUTION, EPINASTINE OPHTHALMIC SOLUTION	Excluded	1	3
Thyroid Hormones	TIROSINT	LEVOTHYROXINE, LEVOXYL, UNITHROID	Excluded	1	3
HIV-Multiclass Combo	TRUVADA	EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE	Excluded	1	4
Inhaled Steroids	QVAR REDIHALER	ARNUITY ELLIPTA, FLOVENT DISKUS, FLOVENT HFA, PULMICORT FLEXHALER	Excluded	1	5
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	ZORVOLEX	CELECOXIB, DICLOFENAC, ETODOLAC, IBUPROFEN, MELOXICAM	Excluded	1	6
Diabetes Monitoring and Testing Supplies	ACCU-CHEK AVIVA PLUS	ASCENCIA (CONTOUR, CONTOUR NEXT) TEST STRIPS	Excluded	1	7
Diabetes Monitoring and Testing Supplies	FREESTYLE TEST STRIPS	ASCENCIA (CONTOUR, CONTOUR NEXT) TEST STRIPS	Excluded	1	8
Gastrointestinal Chloride Channel Activators	AMITIZA	POLYETHYLENE GLYCOL 3350 ORAL POWDER, LACTULOSE, LINZESS, SYMPROIC	Excluded	1	8
Insulin	LEVEMIR FLEXTOUCH	LANTUS, TOUJEO	Excluded	1	8
Angiotensin II Receptor Antagonists & Combos	MICARDIS HCT	TELMISARTAN-HYDROCHLOROTHIAZIDE	Excluded	1	9

OPTUMRx®

ESP
(Enhanced Savings Program)

Key Features and Benefits

Free Program
to clients as a value-add to the client's members. Member communication materials and distribution costs are covered.

Same Card
is used as the program is integrated into the member's existing pharmacy benefit.

Pharmacy Network
including over 67,000 retail pharmacies nationwide.



Member Savings
can be as high as 85% off a cash purchase, with the average program savings at 47%.



Clinical Value
includes these claims and therefore enhances DUR and possibly narrows gaps in care. This increases the view of member's medication intake.

Enhanced Savings Program (ESP) Overview

How ESP Works

1. 

- John takes his prescription to the pharmacy, using the same insurance card.

2. 

- Pharmacy submits John's claim to OptumRx and receives a Reject 70 message.

3. 

- Pharmacy receives a paid claim, with the discounted cost, and a point of sale message of "Add'l discount applied independent of Rx coverage". ESP discounts and messaging will only apply when a single R70 edit appears. ESP will not apply for multiple rejects. (example: drug is rejected because it is filled too early or has reached the maximum refills)

4. 

- John purchases his prescription at the discounted rate through the Enhanced Savings Program.

ADDITIONAL INFORMATION

Member Communications: It is recommended that member letters are sent to introduce the member of the new program. Letters may also be emailed. It is critical that the communication is sent out for member awareness.

Discount Price: The amount paid by John does not apply to his deductible or out of pocket maximum.

Pharmacy: Although the pharmacy received a POS message of 'xxx', the pharmacist may not explain to John that a secondary benefit was applied.

OPTUMRx®

Client reporting

- Enhanced Savings Program reporting includes:
  - Age Range.
  - Number of Rxs.
  - Unique Utilizers.
  - Total U&C Amount.
  - Total Member Cost.
  - Member Savings.
  - Member Savings %.


RxTRACK™ Data Warehousing

Powered by RxTRACK®

CONFIDENTIAL

DHC1020 - Gender Age Range or Brand Generic Utilization

Between 2012-09-01 and 2012-09-30

Age Range	% of Number of Rxs	Number of Rxs	Unique Utilizers	Total U&C Amount	Total Member Cost	Member Savings	Member Savings %
75-84							
65-74							
85+							
55-64							
45-54							
35-44							
20-34							
Top 10 Total							



Available now: LCTRx reporting through RxTrack

Coming in June 2017: LORx and LCTRx reporting through Integrated Data Warehouse

OPTUMRx®

ORx Portal & ORx Mobile – Self Service on-line tool

ORx Portal



ORx Mobile



Optum Perks

AN ENGAGING BRAND FOR CONSUMERS:

OPTUM PERKS

Helping our members when they don’t have coverage



Optum Perks™ Content provided in PDF and Digitally

Education & Awareness







AN ENGAGING BRAND FOR members:

OPTUM PERKS

FREE
to clients/consumers

Promotes
LOYALTY
to your company/association

HELPS
your employees/consumers save on prescriptions

Accepted at
62,000+
pharmacies